192 related articles for article (PubMed ID: 28272462)
1. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma.
Zhang S; Wang Y; Chen M; Sun L; Han J; Elena VK; Qiao H
Sci Rep; 2017 Mar; 7():44033. PubMed ID: 28272462
[TBL] [Abstract][Full Text] [Related]
2. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract][Full Text] [Related]
3. Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.
Wang Q; Yang H; Wu L; Yao J; Meng X; Jiang H; Xiao C; Wu F
Thyroid; 2016 Dec; 26(12):1719-1732. PubMed ID: 27758138
[TBL] [Abstract][Full Text] [Related]
4. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma.
Lan X; Zhang H; Wang Z; Dong W; Sun W; Shao L; Zhang T; Zhang D
Gene; 2015 Sep; 569(1):109-17. PubMed ID: 26003293
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
7. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
8. Identification of hub genes in papillary thyroid carcinoma: robust rank aggregation and weighted gene co-expression network analysis.
Liu Y; Chen TY; Yang ZY; Fang W; Wu Q; Zhang C
J Transl Med; 2020 Apr; 18(1):170. PubMed ID: 32299435
[TBL] [Abstract][Full Text] [Related]
9. Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer.
Gong Y; Yang J; Wu W; Liu F; Su A; Li Z; Zhu J; Wei T
PLoS One; 2018; 13(5):e0197007. PubMed ID: 29723302
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of long noncoding RNA-mRNA co-expression patterns in thyroid cancer.
Du Y; Xia W; Zhang J; Wan D; Yang Z; Li X
Mol Biosyst; 2017 Sep; 13(10):2107-2115. PubMed ID: 28817151
[TBL] [Abstract][Full Text] [Related]
11. Network-based meta-analysis in the identification of biomarkers for papillary thyroid cancer.
Zhao H; Li H
Gene; 2018 Jun; 661():160-168. PubMed ID: 29625265
[TBL] [Abstract][Full Text] [Related]
12. Systems Biology Approaches to Investigate Genetic and Epigenetic Molecular Progression Mechanisms for Identifying Gene Expression Signatures in Papillary Thyroid Cancer.
Yeh SJ; Lin CY; Li CW; Chen BS
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126066
[TBL] [Abstract][Full Text] [Related]
13. The Landscape of Circular RNA Expression Profiles in Papillary Thyroid Carcinoma Based on RNA Sequencing.
Lan X; Xu J; Chen C; Zheng C; Wang J; Cao J; Zhu X; Ge M
Cell Physiol Biochem; 2018; 47(3):1122-1132. PubMed ID: 29847813
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma.
Attia AS; Hussein S; Sameh H; Khalil A; Waley AB; Matar I; Sameh R
Cancer Biomark; 2024; 39(3):211-221. PubMed ID: 38073379
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of long noncoding RNAs in human papillary thyroid carcinoma.
Cao Y; Shi C; Li J; Liang Y; Qiu J; Yuan L; Yong Z; Zhang DX; Shi GQ
Neoplasma; 2019 Mar; 66(2):245-251. PubMed ID: 30569720
[TBL] [Abstract][Full Text] [Related]
17. A novel lncRNA-miRNA-mRNA network analysis identified the hub lncRNA RP11-159F24.1 in the pathogenesis of papillary thyroid cancer.
Jiang W; Zhan H; Jiao Y; Li S; Gao W
Cancer Med; 2018 Dec; 7(12):6290-6298. PubMed ID: 30474931
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of long noncoding RNA H19 contributes to the proliferation and migration of papillary thyroid carcinoma.
Lan X; Sun W; Dong W; Wang Z; Zhang T; He L; Zhang H
Gene; 2018 Mar; 646():98-105. PubMed ID: 29287713
[TBL] [Abstract][Full Text] [Related]
19. Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma.
Wang P; Pei R; Lu Z; Rao X; Liu B
J Chin Med Assoc; 2013 Mar; 76(3):135-9. PubMed ID: 23497965
[TBL] [Abstract][Full Text] [Related]
20. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
